首页> 外文期刊>The journal of obstetrics and gynaecology research >Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2013 and Treatment Annual Report for 2008
【24h】

Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2013 and Treatment Annual Report for 2008

机译:日本妇产科学会妇科肿瘤学委员会年度报告:2013年患者年度报告和2008年治疗年度报告

获取原文
获取原文并翻译 | 示例
       

摘要

The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. We present the Patient Annual Report for 2013 and the Treatment Annual Report for 2008. Data on 7280 patients with cervical cancer, 8952 with endometrial cancer, 5792 with ovarian cancer and 1903 with ovarian borderline tumor for whom treatment was initiated in 2013 were summarized in the Patient Annual Report. Stage I accounted for 56.7%, stage II for 23.4%, stage III for 9.8% and stage IV for 10.2% of all patients with cervical cancer. Stage I accounted for 71.7%, stage II for 6.5%, stage III for 14.5% and stage IV for 7.3% of all patients with endometrial cancer. Stage I accounted for 42.2%, stage II for 9.8%, stage III for 28.2% and stage IV for 8.3% of all patients with ovarian cancer. Data on the prognosis of 3658 patients with cervical cancer, 4159 with endometrial cancer and 2866 with ovarian cancer for whom treatment was initiated in 2008 were analyzed in the Treatment Annual Report. Survival was analyzed by using the Kaplan-Meier method, the log-rank test and the Wilcoxon test. The 5-year overall survival rates for patients with cervical cancer were 93.0% for stage I, 73.1% for stage II, 55.2% for stage III and 24.2% for stage IV. The equivalent rates for patients with endometrial cancer were 94.5%, 90.3%, 74.2% and 24.0%, respectively; and those for patients with ovarian cancer (surface epithelial-stromal tumors) were 90.5%, 73.5%, 48.1% and 29.4%, respectively.
机译:日本妇产科学会从会员机构收集并分析有关妇科癌症的年度数据。我们提供2013年的患者年度报告和2008年的治疗年度报告。2013年开始治疗的7280例宫颈癌患者,8952例子宫内膜癌,5792例卵巢癌和1903例卵巢交界性肿瘤的数据进行了总结。患者年度报告。在所有子宫颈癌患者中,第一阶段占56.7%,第二阶段占23.4%,第三阶段占9.8%,第四阶段占10.2%。在所有子宫内膜癌患者中,I期占71.7%,II期占6.5%,III期占14.5%,IV期占7.3%。在所有卵巢癌患者中,I期占42.2%,II期占9.8%,III期占28.2%,IV期占8.3%。在《治疗年度报告》中分析了2008年开始治疗的3658例宫颈癌,4159例子宫内膜癌和2866例卵巢癌的预后。使用Kaplan-Meier方法,对数秩检验和Wilcoxon检验分析生存率。宫颈癌患者的5年总生存率I期为93.0%,II期为73.1%,III期为55.2%,IV期为24.2%。子宫内膜癌患者的等效率分别为94.5%,90.3%,74.2%和24.0%;卵巢癌(表面上皮间质瘤)患者分别为90.5%,73.5%,48.1%和29.4%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号